Equities

Diaceutics PLC

DXRX:LSE

Diaceutics PLC

Health CareHealth Care Providers
  • Price (GBX)117.50
  • Today's Change0.00 / 0.00%
  • Shares traded15.10k
  • 1 Year change32.02%
  • Beta0.5450
Data delayed at least 20 minutes, as of Nov 22 2024 16:37 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Diaceutics PLC's net income fell from a gain of 724.00k to a loss of 1.75m despite revenues that grew 21.51% from 19.50m to 23.70m. An increase in the selling, general and administrative costs as a percentage of sales from 83.47% to 96.14% was a component in the falling net income despite rising revenues.
Gross margin83.30%
Net profit margin-10.90%
Operating margin-17.00%
Return on assets-6.22%
Return on equity-7.13%
Return on investment-6.90%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Diaceutics PLC fell by 3.17m. However, the company earned 1.31m from its operations for a Cash Flow Margin of 5.53%. In addition the company used 4.21m on investing activities and also paid 239.00k in financing cash flows.
Cash flow per share0.027
Price/Cash flow per share43.86
Book value per share0.4573
Tangible book value per share0.2859
More ▼

Balance sheet in GBPView more

Diaceutics PLC has little financial risk as the capital structure does not rely on leverage.
Current ratio4.85
Quick ratio--
Total debt/total equity0.0293
Total debt/total capital0.0284
More ▼

Growth rates in GBP

Year on year, growth in earnings per share excluding extraordinary items dropped -346.49%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-5,086.15
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.